IDEAS home Printed from https://ideas.repec.org/f/pto443.html
   My authors  Follow this author

Adrian Towse

Personal Details

First Name:Adrian
Middle Name:
Last Name:Towse
Suffix:
RePEc Short-ID:pto443
[This author has chosen not to make the email address public]

Affiliation

Office of Health Economics

London, United Kingdom
http://www.ohe.org/
RePEc:edi:ohecouk (more details at EDIRC)

Research output

as
Jump to: Working papers Articles Books

Working papers

  1. Adrian Towse & Rachel Silverman Bonnifield, 2022. "An Ambitious USG Advanced Commitment for Subscription-Based Purchasing of Novel Antimicrobials and Its Expected Return on Investment," Policy Papers 277, Center for Global Development.
  2. Dimitrios Kourouklis & Mikel Berdud & Mireia Jofre-Bonet & Adrian Towse, 2022. "Alternative funding models for medical innovation: the role of product development partnerships in product innovation for infectious diseases," Post-Print hal-03710938, HAL.
  3. Adrian Towse, 2020. "How Should the World Pay for a COVID-19 Vaccine?," Monograph 002287, Office of Health Economics.
  4. Amanda Cole;Adrian Towse;Bernarda Zamora, 2019. "Documento de debate sobre la fijación de precios en función de la indicación (IBP) ¿Deben variar los precios de los medicamentos según la indicación?," Briefing 002176, Office of Health Economics.
  5. Mikel Berdud & Kalipso Chalkidou & Emma Dean & Jimena Ferraro & Lou Garrison & Cassandra Nemzoff & Adrian Towse, 2019. "The Future of Global Health Procurement: Issues around Pricing Transparency," Working Papers 507, Center for Global Development.
  6. Amanda Cole;Adrian Towse;Bernarda Zamora, 2019. "Indication-Based Pricing (IBP) Discussion Paper: Should drug prices differ by indication?," Briefing 002165, Office of Health Economics.
  7. Margherita Neri;Adrian Towse;Martina Garau, 2018. "Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward," Briefing 002084, Office of Health Economics.
  8. Adrian Towse;Jimena Ferraro;Jorge Mestre-Ferrandiz, 2017. "Incentives for New Drugs to Tackle Anti-Microbial Resistance," Briefing 001842, Office of Health Economics.
  9. Margherita Neri;Adrian Towse, 2017. "Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help?," Briefing 001922, Office of Health Economics.
  10. Amanda Cole;Adrian Towse;Michelle Mujoomdar;Arnold Chan;Franz Pichler, 2016. "How Can Health Technology Assessments in the Asia-Pacific Area Respond to Increased Clinical Uncertainty as a Consequence of Expedited US and EU Regulatory Processes?," Briefing 001740, Office of Health Economics.
  11. Jorge Mestre-Ferrandiz;Renato Dellamano;Michele Pistollato;Adrian Towse, 2015. "Multi-indication Pricing: Pros, Cons and Applicability to the UK," Seminar Briefing 001653, Office of Health Economics.
  12. Adrian Towse, 2014. "Comparative and Relative Effectiveness: A Challenge For Health Systems, Regulators, or Pharmaceutical Companies?," Occasional Paper 001561, Office of Health Economics.
  13. Adrian Towse;Paul Barnsley;Sarah Karlsberg-Schaffer;Jon Sussex, 2013. "Critique of CHE Research Paper 81: Methods for the Estimation of the NICE Cost Effectiveness Threshold," Occasional Paper 000106, Office of Health Economics.
  14. Patricia M. Danzon & Adrian K. Towse & Jorge Mestre-Ferrandiz, 2012. "Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context," NBER Working Papers 18593, National Bureau of Economic Research, Inc.
  15. Lou Garrison;Ruth Puig-Peiro;Adrian Towse, 2012. "The Use of Pay-for-Performance for Drugs: Can It Improve Incentives for Innovation?," Occasional Paper 000167, Office of Health Economics.
  16. Patricia Danzon;Martina Garau;Adrian Towse, 2011. "Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution?," Occasional Paper 000191, Office of Health Economics.
  17. Patricia M. Danzon & Andrew W. Mulcahy & Adrian K. Towse, 2011. "Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition and Procurement," NBER Working Papers 17174, National Bureau of Economic Research, Inc.
  18. Priya Sharma;Adrian Towse, 2010. "New Drugs to Tackle Antimicrobial Resistance: EU Policy Options," Occasional Paper 000216, Office of Health Economics.
  19. Deven Chauhan;Jorge Mestre-Ferrandiz;Adrian Towse, 2008. "The Market for Biosimilars: Evolution and Policy Options," Briefing 000238, Office of Health Economics.
  20. Martin Buxton;Adrian Towse, 2006. "Three Challenges to Achieving Better Analysis for Better Decisions: Generalisability, Complexity and Thresholds," Briefing 000267, Office of Health Economics.
  21. Paul Fenn;Alastair Gray;Neil Rickman;Rodrigo Salinas;Adrian Towse, 2003. "Reducing Harm to Patients in the National Health Service. Will the Government’s Compensation Proposals Help?," Briefing 000484, Office of Health Economics.
  22. Michael F. Drummond;Adrian Towse, 1998. "From Efficacy to Cost-Effectiveness," Briefing 000438, Office of Health Economics.
  23. Martin Cave;Adrian Towse, 1997. "Regulating Prices Paid by the NHS for Medicines Supplied by the UK-Based Pharmaceutical Industry," Briefing 000427, Office of Health Economics.
    repec:ohe:briefg:001837 is not listed on IDEAS
    repec:ohe:briefg:001838 is not listed on IDEAS
    repec:ohe:briefg:000075 is not listed on IDEAS
    repec:ohe:conrep:001699 is not listed on IDEAS
    repec:ohe:conrep:000265 is not listed on IDEAS
    repec:ohe:respap:000188 is not listed on IDEAS
    repec:ohe:respap:001848 is not listed on IDEAS
    repec:ohe:briefg:001851 is not listed on IDEAS
    repec:ohe:respap:001811 is not listed on IDEAS
    repec:ohe:respap:000037 is not listed on IDEAS
    repec:ohe:conrep:000212 is not listed on IDEAS
    repec:ohe:respap:000211 is not listed on IDEAS
    repec:ohe:conrep:000050 is not listed on IDEAS
    repec:ohe:conrep:001944 is not listed on IDEAS
    repec:ohe:respap:001998 is not listed on IDEAS
    repec:ohe:conrep:000192 is not listed on IDEAS
    repec:ohe:conrep:001743 is not listed on IDEAS
    repec:ohe:respap:000177 is not listed on IDEAS
    repec:ohe:respap:001764 is not listed on IDEAS
    repec:ohe:conrep:001748 is not listed on IDEAS
    repec:ohe:conrep:000234 is not listed on IDEAS
    repec:ohe:respap:001997 is not listed on IDEAS
    repec:ohe:briefg:001836 is not listed on IDEAS
    repec:ohe:conrep:001784 is not listed on IDEAS
    repec:ohe:respap:000160 is not listed on IDEAS
    repec:ohe:conrep:001660 is not listed on IDEAS
    repec:ohe:briefg:001835 is not listed on IDEAS
    repec:ohe:conrep:001978 is not listed on IDEAS
    repec:ohe:occpap:001600 is not listed on IDEAS
    repec:ohe:conrep:001802 is not listed on IDEAS

Articles

  1. Dimitrios Kourouklis & Mikel Berdud & Mireia Jofre-Bonet & Adrian Towse, 2023. "Alternative funding models for medical innovation: the role of product development partnerships in product innovation for infectious diseases," Applied Economics Letters, Taylor & Francis Journals, vol. 30(16), pages 2195-2199, September.
  2. Chris Sampson & Bernarda Zamora & Sam Watson & John Cairns & Kalipso Chalkidou & Patricia Cubi-Molla & Nancy Devlin & Borja García-Lorenzo & Dyfrig A. Hughes & Ashley A. Leech & Adrian Towse, 2022. "Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy," Applied Health Economics and Health Policy, Springer, vol. 20(5), pages 651-667, September.
  3. Chris Sampson & Isobel Firth & Adrian Towse, 2021. "Health Opportunity Costs and Expert Elicitation: A Comment on Soares et al," Medical Decision Making, , vol. 41(3), pages 255-257, April.
  4. Bengt Jönsson & Grace Hampson & Jonathan Michaels & Adrian Towse & J.-Matthias Graf Schulenburg & Olivier Wong, 2019. "Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(3), pages 427-438, April.
  5. Michael Drummond & Adrian Towse, 2019. "Is rate of return pricing a useful approach when value-based pricing is not appropriate?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(7), pages 945-948, September.
  6. Towse, Adrian & Hoyle, Christopher K. & Goodall, Jonathan & Hirsch, Mark & Mestre-Ferrandiz, Jorge & Rex, John H., 2017. "Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation," Health Policy, Elsevier, vol. 121(10), pages 1025-1030.
  7. Mikel Berdud & Adrian Towse & Hannah Kettler, 2016. "Fostering incentives for research, development, and delivery of interventions for neglected tropical diseases: lessons from malaria," Oxford Review of Economic Policy, Oxford University Press and Oxford Review of Economic Policy Limited, vol. 32(1), pages 64-87.
  8. Jorge Mestre-Ferrandiz & Adrian Towse & Mikel Berdud, 2016. "Biosimilars: How Can Payers Get Long-Term Savings?," PharmacoEconomics, Springer, vol. 34(6), pages 609-616, June.
  9. Adrian Towse & Michele Pistollato & Jorge Mestre-Ferrandiz & Zeba Khan & Satyin Kaura & Louis Garrison, 2015. "European Union Pharmaceutical Markets: A Case for Differential Pricing?," International Journal of the Economics of Business, Taylor & Francis Journals, vol. 22(2), pages 263-275, July.
  10. Patricia M. Danzon & Andrew W. Mulcahy & Adrian K. Towse, 2015. "Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement," Health Economics, John Wiley & Sons, Ltd., vol. 24(2), pages 238-252, February.
  11. Patricia Danzon & Adrian Towse & Jorge Mestre‐Ferrandiz, 2015. "Value‐Based Differential Pricing: Efficient Prices for Drugs in a Global Context," Health Economics, John Wiley & Sons, Ltd., vol. 24(3), pages 294-301, March.
  12. Michael Drummond & Adrian Towse, 2014. "Orphan drugs policies: a suitable case for treatment," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(4), pages 335-340, May.
  13. Jon Sussex & Adrian Towse & Nancy Devlin, 2013. "Operationalizing Value-Based Pricing of Medicines," PharmacoEconomics, Springer, vol. 31(1), pages 1-10, January.
  14. Michael Drummond & Adrian Towse, 2012. "Is it time to reconsider the role of patient co-payments for pharmaceuticals in Europe?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(1), pages 1-5, February.
  15. Adrian Towse & Priya Sharma, 2011. "Incentives for R&D for New Antimicrobial Drugs," International Journal of the Economics of Business, Taylor & Francis Journals, vol. 18(2), pages 331-350.
  16. Adrian Towse, 2007. "If it ain't broke, don't price fix it: the OFT and the PPRS," Health Economics, John Wiley & Sons, Ltd., vol. 16(7), pages 653-665, July.
  17. Michael Drummond & Anne Mason & Adrian Towse, 2006. "The desirability and feasibility of economic studies of drugs post-launch," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(1), pages 5-6, March.
  18. Diego Ossa & Adrian Towse, 2004. "Genetic screening, health care and the insurance industry," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 5(2), pages 116-121, May.
  19. Adrian Towse & Patricia Danzon, 1999. "Medical negligence and the NHS: an economic analysis," Health Economics, John Wiley & Sons, Ltd., vol. 8(2), pages 93-101, March.
  20. Mason, Anne & Drummond, Michael & Towse, Adrian, 1999. "Is disease management relevant in Europe: some evidence from the United Kingdom," Health Policy, Elsevier, vol. 48(1), pages 69-77, July.
  21. Adrian Towse, 1994. "The Political Economy of Healthcare. By David Resisman. MacMillan Press, London, 1993. No. of pages: 267. ISBN: 0‐333‐58579‐8," Health Economics, John Wiley & Sons, Ltd., vol. 3(5), pages 347-348, September.

Books

  1. Jorge Mestre-Ferrandiz;Jon Sussex;Adrian Towse, 2012. "The R&D Cost of a New Medicine," Monograph 000135, Office of Health Economics.
  2. Priya Sharma;Adrian Towse, 2011. "New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options," Monograph 000184, Office of Health Economics.
  3. Adrian Towse;Nancy Mattison;Jorge Mestre-Ferrandiz, 2010. "Biosimilars: How Much Entry and Price Competition Will Result?," Monograph 000195, Office of Health Economics.
  4. Anne R. Mason;Michael F. Drummond;Adrian Towse, 2006. "Economic Post-Launch Studies: Matching the Desirable with the Feasible," Monograph 000268, Office of Health Economics.
  5. Hannah Kettler;Adrian Towse, 2002. "Public Private Partnerships for Research and Development: Medicines and Vaccines for Diseases of Poverty," Monograph 000479, Office of Health Economics.
  6. Anne R. Mason;Michael F. Drummond;Jonathan Cooke;Adrian Towse, 2002. "Influencing Prescribing in a Primary Care Led NHS," Monograph 000476, Office of Health Economics.
  7. Clive Pritchard;Nancy Devlin;Adrian Towse, 2002. "Cost-Effectiveness Thresholds: Economic and ethical issues," Monograph 000473, Office of Health Economics.
  8. Anne R. Mason;Michael F. Drummond;Adrian Towse, 1999. "Disease Management, the NHS and the Pharmaceutical Industry," Monograph 000446, Office of Health Economics.
  9. Adrian Towse, 1997. "Guidelines for the Economic Evaluation of Pharmaceuticals: Can the UK learn from Australia and Canada?," Monograph 000423, Office of Health Economics.
  10. Adrian Towse, 1995. "Financing Health Care in the UK: A Discussion of NERA’s Prototype Model to Replace the NHS," Monograph 000409, Office of Health Economics.
  11. Adrian Towse, 1995. "Industrial Policy and the Pharmaceutical Industry," Monograph 000414, Office of Health Economics.
  12. David Hale;Adrian Towse, 1995. "Value of the Pharmaceutical Industry to the UK Economy," Monograph 000415, Office of Health Economics.
    RePEc:ohe:monogr:000242 is not listed on IDEAS

More information

Research fields, statistics, top rankings, if available.

Statistics

Access and download statistics for all items

Co-authorship network on CollEc

NEP Fields

NEP is an announcement service for new working papers, with a weekly report in each of many fields. This author has had 18 papers announced in NEP. These are the fields, ordered by number of announcements, along with their dates. If the author is listed in the directory of specialists for this field, a link is also provided.
  1. NEP-HEA: Health Economics (13) 2011-07-13 2018-05-14 2018-05-21 2018-05-21 2018-05-21 2018-05-21 2018-05-21 2018-05-21 2018-05-21 2018-05-21 2018-05-21 2018-05-21 2018-05-28. Author is listed
  2. NEP-SEA: South East Asia (5) 2018-05-21 2018-05-21 2018-05-21 2018-05-21 2018-05-21. Author is listed
  3. NEP-COM: Industrial Competition (3) 2011-07-13 2012-12-15 2018-05-21
  4. NEP-ENV: Environmental Economics (2) 2018-05-21 2018-05-28
  5. NEP-BEC: Business Economics (1) 2019-05-20
  6. NEP-ENE: Energy Economics (1) 2018-05-28
  7. NEP-EUR: Microeconomic European Issues (1) 2018-05-21
  8. NEP-HME: Heterodox Microeconomics (1) 2011-07-13
  9. NEP-IAS: Insurance Economics (1) 2018-05-21
  10. NEP-IPR: Intellectual Property Rights (1) 2018-05-21
  11. NEP-PPM: Project, Program and Portfolio Management (1) 2018-05-28
  12. NEP-REG: Regulation (1) 2019-05-06

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.

To update listings or check citations waiting for approval, Adrian Towse should log into the RePEc Author Service.

To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.

To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.

Please note that most corrections can take a couple of weeks to filter through the various RePEc services.

IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.